Interleukin Genetics Gets NYSE Amex Extension for Stock Listing | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Interleukin Genetics today said that the corporate compliance staff of the New York Stock Exchange Amex has granted the firm an extension to meet the exchange's continued listing standards.

The Waltham, Mass.-based genetic test maker will remain listed on the NYSE Amex up to June 23, subject to periodic review by the exchange staff of the firm's progress toward regaining compliance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.